echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine's PD-1 Inhibitor Carrelizumab Approved for New Indication

    Hengrui Medicine's PD-1 Inhibitor Carrelizumab Approved for New Indication

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 10, China's National Food and Drug Administration (NMPA) recently announced that Hengrui Medicine's PD-1 inhibitor carrelizumab has been approved for the marketing of two new indications


    Screenshot source: NMPA official website

    Carrelizumab for injection is a humanized anti-PD-1 monoclonal antibody independently developed by Hengrui Pharmaceuticals, which can bind to human PD-1 receptors and block the PD-1/PD-L1 pathway to restore the body’s Anti-tumor immunity, thus forming the basis of cancer immunotherapy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.